We are live on ! Find out more
NRSN icon

NeuroSense Therapeutics
NRSN

8 hedge funds and large institutions have $304K invested in NeuroSense Therapeutics in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more capital invested

Capital invested by funds: $111K → $304K (+$193K)

0.19% more ownership

Funds ownership: 1.04% → 1.22% (+0.19%)

0% more funds holding

Funds holding: 8 → 8 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
8
Holders Change
–
Holders Change %
0%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$95.7K
2
WP
Woodline Partners
California
+$26.4K
3
UBS Group
UBS Group
Switzerland
+$8.64K

Top Sellers

Rank Fund Capital Flow
1
MIH
Meitav Investment House
Israel
-$60.6K
2
SRL
Scientech Research LLC
New Jersey
-$10.1K
3
HF
HRT Financial
New York
-$10K

NRSN Hedge Fund Activity: Q1 2024 in Review

8 of the 6,961 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics (NRSN) for Q1 2024, worth a combined $304K — up 175% from $111K a quarter earlier.

Fund positioning in NRSN was balanced in Q1 2024: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $95.7K. The largest seller was Meitav Investment House, cutting an estimated $60.6K.

  • 8 institutional investors held NeuroSense Therapeutics (NRSN) as of Q1 2024, unchanged from Q4 2023.
  • Funds reported $304K of NeuroSense Therapeutics stock for Q1 2024, up 175% quarter-over-quarter.
  • 2 funds opened new NeuroSense Therapeutics positions in Q1 2024 and 2 closed out, a net change of 0 holders.
  • The largest NeuroSense Therapeutics buyer in Q1 2024 was Renaissance Technologies, an estimated $95.7K added.
  • The largest NeuroSense Therapeutics seller in Q1 2024 was Meitav Investment House, an estimated $60.6K sold.

Based on aggregated 13F filings for Q1 2024.